CY1110335T1 - Τρικυκλικοι αναστολεις parp - Google Patents

Τρικυκλικοι αναστολεις parp

Info

Publication number
CY1110335T1
CY1110335T1 CY20101100309T CY101100309T CY1110335T1 CY 1110335 T1 CY1110335 T1 CY 1110335T1 CY 20101100309 T CY20101100309 T CY 20101100309T CY 101100309 T CY101100309 T CY 101100309T CY 1110335 T1 CY1110335 T1 CY 1110335T1
Authority
CY
Cyprus
Prior art keywords
tricyclic
parp
suspensions
relates
tricyclic lactam
Prior art date
Application number
CY20101100309T
Other languages
English (en)
Inventor
Thomas Helleday
Nicola Curtin
Original Assignee
Cancer Research Technology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0317466.1A external-priority patent/GB0317466D0/en
Priority claimed from GB0408524A external-priority patent/GB0408524D0/en
Application filed by Cancer Research Technology Limited filed Critical Cancer Research Technology Limited
Publication of CY1110335T1 publication Critical patent/CY1110335T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/0203—NAD+ ADP-ribosyltransferase (2.4.2.30), i.e. tankyrase or poly(ADP-ribose) polymerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Abstract

Η εφεύρεση σχετίζεται με παράγωγα ινδόλης τρικυκλικής λακτάμης και παράγωγα βενζιμιδαζόλης τρικυκλικής λακτάμης και με την χρήση αυτών όσον αφορά την αναστολή της δραστηριότητας του ενζύμου PARP. Η εφεύρεση σχετίζεται επίσης με την χρήση αυτών των ένωσεων όσον αφορά την παρασκευή φαρμάκων.
CY20101100309T 2003-07-25 2010-03-31 Τρικυκλικοι αναστολεις parp CY1110335T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0317466.1A GB0317466D0 (en) 2003-07-25 2003-07-25 Use
GB0408524A GB0408524D0 (en) 2004-04-16 2004-04-16 Use
EP04743516A EP1660095B1 (en) 2003-07-25 2004-07-23 Tricyclic parp inhibitors

Publications (1)

Publication Number Publication Date
CY1110335T1 true CY1110335T1 (el) 2015-01-14

Family

ID=34117642

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100309T CY1110335T1 (el) 2003-07-25 2010-03-31 Τρικυκλικοι αναστολεις parp

Country Status (23)

Country Link
US (2) US7351701B2 (el)
EP (1) EP1660095B1 (el)
JP (2) JP5466814B2 (el)
KR (1) KR101138471B1 (el)
AT (1) ATE454893T1 (el)
AU (1) AU2004261462B2 (el)
BR (1) BRPI0412899B1 (el)
CA (1) CA2533332C (el)
CY (1) CY1110335T1 (el)
DE (1) DE602004025123D1 (el)
DK (1) DK1660095T3 (el)
ES (1) ES2339663T3 (el)
HK (1) HK1084602A1 (el)
IL (1) IL173336A (el)
MX (1) MXPA06000993A (el)
NO (1) NO334610B1 (el)
NZ (1) NZ544989A (el)
PL (1) PL1660095T3 (el)
PT (1) PT1660095E (el)
RU (1) RU2404183C2 (el)
SI (1) SI1660095T1 (el)
WO (1) WO2005012305A2 (el)
ZA (1) ZA200600679B (el)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030020488A (ko) * 2001-08-29 2003-03-10 강정훈 대나무 추출물을 유효성분으로 하는 화상치료용 조성물
BRPI0408996A (pt) * 2003-03-31 2006-03-28 Pfizer saia de inibidores tricìclicos de poli(adpp-ribose) polimerases
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
MXPA06000993A (es) 2003-07-25 2006-08-31 Cancer Rec Tech Ltd Inhbidores triciclicos de parp.
DK2305221T3 (en) * 2003-12-01 2015-08-24 Kudos Pharm Ltd DNA damage repair inhibitors for the treatment of cancer
BRPI0516766A (pt) * 2004-09-22 2008-09-16 Pfizer formas polimórficas e amorfas do sal de fosfato de 8-flúor-2{4-[(metilamino)metil]fenil}-1,3,4,5-tetraidro- 6h-azepino[5,4,3-cd]indol-6-ona, composição farmacêutica, formas de dosagens e respectivo uso
JP2008513435A (ja) * 2004-09-22 2008-05-01 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤を含む治療用組成物
MX2007008771A (es) 2005-01-19 2007-09-11 Mgi Gp Inc Compuestos de diazabenzo [des] antracen-3-ona y metodos para inhibir parp.
ZA200800907B (en) 2005-07-18 2010-04-28 Bipar Sciences Inc Treatment of cancer
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US8143447B2 (en) 2006-09-05 2012-03-27 Bipar Sciences, Inc. Treatment of cancer
WO2008030891A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
JP5439380B2 (ja) 2007-10-03 2014-03-12 エーザイ インク． Ｐａｒｐ阻害化合物、組成物及び使用方法
MX2010005221A (es) * 2007-11-12 2010-09-28 Bipar Sciences Inc Tratamiento de cancer de utero y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes antitumorales.
EP2217227B1 (en) 2007-11-12 2013-08-21 BiPar Sciences, Inc. Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
RU2010136966A (ru) * 2008-02-04 2012-03-20 Байпар Сайенсиз, Инк. (Us) Способы диагностики и лечения заболеваний, опосредованных parp
GB0804755D0 (en) 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
EP4166558A1 (en) 2010-02-12 2023-04-19 Pfizer Inc. Salts and polymorphs of 8-fluoro-2-{4- [(methylamino)methyl]phenyl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one
DK3012329T3 (da) 2010-06-18 2017-11-20 Myriad Genetics Inc Fremgangsmåder og materialer til at vurdere tab af heterozygositet
US9512485B2 (en) 2010-08-24 2016-12-06 Dana-Farber Cancer Institute. Inc. Methods for predicting anti-cancer response
EP2646428B1 (en) 2010-12-02 2016-06-01 Shanghai De Novo Pharmatech Co Ltd. Heterocyclic derivatives, preparation processes and medical uses thereof
EP2709618A4 (en) * 2011-05-10 2014-11-05 UNIVERSITé LAVAL METHOD FOR THE TREATMENT AND DIAGNOSIS OF PULMONARY ARTERIAL HYPERTENSION
CA2839210A1 (en) 2011-06-17 2012-12-20 Myriad Genetics, Inc. Methods and materials for assessing allelic imbalance
MX368261B (es) 2011-07-22 2019-09-25 Pacylex Pharmaceuticals Inc Letalidad sintetica y el tratamiento de cancer.
FI2794907T4 (fi) 2011-12-21 2023-03-27 Menetelmiä ja materiaaleja heterotsygoottisuuden menettämisen arvioimiseksi
DK2817630T3 (en) 2012-02-23 2018-10-08 Childrens Medical Center Methods for predicting an anti-cancer response
ES2658867T3 (es) 2012-06-07 2018-03-12 Institut Curie Métodos para detectar la inactivación de la ruta de recombinación homóloga (BRCA1/2) en tumores humanos
CN104754942A (zh) * 2012-09-05 2015-07-01 拜尔农作物科学股份公司 取代的苯并二氮杂卓酮和苯并氮杂卓酮或它们的盐作为对抗植物非生物胁迫的活性物质的用途
US10308986B2 (en) 2013-03-14 2019-06-04 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
JP6625045B2 (ja) 2013-04-05 2019-12-25 ミリアド・ジェネティックス・インコーポレイテッド 相同組換え欠損を評価するための方法および材料
EP3080292B1 (en) 2013-12-09 2022-02-02 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
EP3686288B1 (en) 2014-08-15 2023-03-08 Myriad Genetics, Inc. Methods and materials for assessing homologous recombination deficiency
CN106794185A (zh) 2014-08-22 2017-05-31 克洛维斯肿瘤有限公司 Rucaparib的高剂量强度片剂
KR20160116831A (ko) 2015-03-31 2016-10-10 (주)아모레퍼시픽 코지산 유도체를 유효성분으로 포함하는 장수 유전자 활성화용 조성물
PL3325662T3 (pl) 2015-07-17 2024-02-26 Pacylex Pharmaceuticals Inc. Wyciszenie epigenetyczne nmt2
PT3325623T (pt) 2015-07-23 2019-09-04 Inst Curie Utilização de uma combinação de molécula dbait e de inibidores de parp para o tratamento do cancro
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
TWI730013B (zh) 2015-11-20 2021-06-11 生華生物科技股份有限公司 用於治療癌症的四環喹諾酮類似物組合療法
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
EP3786171A1 (en) 2016-04-01 2021-03-03 Nohms Technologies, Inc. Modified ionic liquids containing phosphorus
WO2018022851A1 (en) 2016-07-28 2018-02-01 Mitobridge, Inc. Methods of treating acute kidney injury
AU2017355402A1 (en) 2016-11-02 2019-05-30 Health Research, Inc. Combination treatment with antibody-drug conjugates and PARP inhibitors
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2018165615A1 (en) 2017-03-09 2018-09-13 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Parp-1 and methods of use thereof
US20200129476A1 (en) 2017-04-28 2020-04-30 Akribes Biomedical Gmbh PARP Inhibitor in Combination with a Glucocorticoid and/or Ascorbic Acid and/or a Protein Growth Factor for the Treatment of Impaired Wound Healing
US10665899B2 (en) 2017-07-17 2020-05-26 NOHMs Technologies, Inc. Phosphorus containing electrolytes
MA51524A (fr) 2018-01-05 2020-11-11 Cybrexa 1 Inc Composés, compositions et méthodes pour le traitement de maladies impliquant des tissus malades acides ou hypoxiques
US20190374550A1 (en) 2018-02-15 2019-12-12 Senhwa Biosciences, Inc. Quinolone analogs and their salts, compositions, and method for their use
JP2021515580A (ja) 2018-03-13 2021-06-24 オンクセオＯｎｘｅｏ がんの治療における獲得耐性に対抗するｄｂａｉｔ分子
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
CN114341162A (zh) 2019-07-10 2022-04-12 赛博克萨2公司 作为治疗剂的细胞毒素的肽缀合物
PE20220485A1 (es) 2019-07-10 2022-04-04 Cybrexa 3 Inc Conjugados peptidicos de agentes dirigidos a microtubulos como terapeuticos
WO2021018298A1 (zh) * 2019-08-01 2021-02-04 南京明德新药研发有限公司 作为parp抑制剂吲哚并七元酰肟化合物
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN115485271A (zh) 2020-04-28 2022-12-16 理森制药股份公司 用作聚(adp-核糖)聚合酶（parp）抑制剂的新型化合物
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
AU2022255809A1 (en) 2021-04-08 2023-10-26 Incozen Therapeutics Pvt. Ltd. Inhibitors of poly(adp-ribose) polymerase
EP4141127A1 (en) 2021-08-30 2023-03-01 Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln Method for assessing homologous recombination deficiency in ovarian cancer cells
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
WO2023233295A1 (en) 2022-06-01 2023-12-07 Ideaya Biosciences, Inc. Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ512731A (en) * 1999-01-11 2004-01-30 Agouron Pharma Tricyclic inhibitors of poly(ADP-ribose) polymerases
ECSP003637A (es) * 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US7449464B2 (en) * 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
BRPI0408996A (pt) * 2003-03-31 2006-03-28 Pfizer saia de inibidores tricìclicos de poli(adpp-ribose) polimerases
MXPA06000993A (es) 2003-07-25 2006-08-31 Cancer Rec Tech Ltd Inhbidores triciclicos de parp.
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
DK2305221T3 (en) * 2003-12-01 2015-08-24 Kudos Pharm Ltd DNA damage repair inhibitors for the treatment of cancer
JP2008513435A (ja) * 2004-09-22 2008-05-01 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤を含む治療用組成物

Also Published As

Publication number Publication date
PL1660095T3 (pl) 2010-07-30
RU2006105652A (ru) 2006-08-10
DK1660095T3 (da) 2010-05-25
MXPA06000993A (es) 2006-08-31
CA2533332C (en) 2012-01-10
WO2005012305A3 (en) 2005-04-07
HK1084602A1 (en) 2006-08-04
IL173336A0 (en) 2006-06-11
ES2339663T3 (es) 2010-05-24
JP5466814B2 (ja) 2014-04-09
CA2533332A1 (en) 2005-02-10
ATE454893T1 (de) 2010-01-15
US20070072841A1 (en) 2007-03-29
JP5580280B2 (ja) 2014-08-27
RU2404183C2 (ru) 2010-11-20
NZ544989A (en) 2009-10-30
KR20060066067A (ko) 2006-06-15
JP2007533601A (ja) 2007-11-22
DE602004025123D1 (en) 2010-03-04
AU2004261462B2 (en) 2010-04-22
ZA200600679B (en) 2011-08-31
PT1660095E (pt) 2010-04-19
BRPI0412899A (pt) 2006-10-03
KR101138471B1 (ko) 2012-04-25
BRPI0412899B1 (pt) 2021-10-05
JP2012087135A (ja) 2012-05-10
NO334610B1 (no) 2014-04-22
US7531530B2 (en) 2009-05-12
US7351701B2 (en) 2008-04-01
US20050143370A1 (en) 2005-06-30
EP1660095B1 (en) 2010-01-13
NO20060928L (no) 2006-02-24
EP1660095A2 (en) 2006-05-31
WO2005012305A2 (en) 2005-02-10
SI1660095T1 (sl) 2010-05-31
AU2004261462A1 (en) 2005-02-10
IL173336A (en) 2014-02-27

Similar Documents

Publication Publication Date Title
CY1110335T1 (el) Τρικυκλικοι αναστολεις parp
CY1107614T1 (el) Νιτροξυπαραγωγα φλουβαστατινης, πραβαστατινης, σεριβαστατινης, ατορβαστατινης και ροσουβαστατινης ως μειωτικοι (περιοριστικοι) παραγοντες-χοληστερινης, με βελτιωμενη αντι-φλεγμονωδη, αντιθρομβοτικην και αντι-αιμοπεταλικην δρασιν
BRPI0409367A (pt) derivados de piperidina inibidores de renina
CY1116816T1 (el) Συνθεσεις ανταγωνιστων pd-1 και μεθοδοι χρησης
PT1224174E (pt) Derivados de benzodiazepina como antagonistas do receptor metabotropico do glutamato
CY1114148T1 (el) Γεφυρωμενες δικυκλικες αρυλο- και γεφυρωμενες δικυκλικες etepoapyλo-υποκατεστημενες τριαζολες χρησιμες ως αναστολεις toy axl
DE60309481D1 (de) Cyclische n-aroylamine als orexinrezeptorantagonisten
TR200002298A2 (tr) 1,2,4,5- Tetrahidro-Benzo [D] azepinler
BR0115436A (pt) Compostos de piperazinilpirazina atuando como antagonistas do receptor 5ht-2 de serotonina
DE60218852D1 (de) Verbindungen
UY28186A1 (es) N-arilheterociclos sustituidos, procedimientos para su preparación, y su empleo como medicamentos.
CY1107054T1 (el) Ενωσεις διτοσυλικου αλατος κιναζολινης
PT1305301E (pt) Benzeno-acetamidas alfa-acilo e alfa-heteroatomo-substituidas activadoras da glucocinase
CO5700775A2 (es) Nuevos derivados triciclicos como antagonistas de ltd4
ATE349440T1 (de) Als antikrebsmittel verwendbare heterocyklische derivate
UY27777A1 (es) Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida
CR6577A (es) Inhibidores triciclicos de poli(adp-ribosa) polimerasas
BRPI0414598A (pt) indóis substituìdos
EA200200742A1 (ru) 1,2-диарилбензимидазолы для лечения заболеваний, связанных с активацией микроглии
SV2002000062A (es) Derivados monofluoroalquilo ref. x-12964
UY27418A1 (es) Formulaciones en combinación de derivados de propanol-amina sustituidos con arilo, junto con otras sustancias activas y su utilización
MA31630B1 (fr) Dérivés de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamides et de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazépine-7-carboxamides, leur préparation et leur application en thérapeutique
BR0113581A (pt) Derivados de aril-piperazinas e seu uso como psicofármacos
BR0115119A (pt) Derivados tricìclicos de indol com atividade antiangiogênica
EA200100802A1 (ru) Применение тианептина при приготовлении лекарственных средств, предназначенных для лечения нейродегенеративных патологий